SAB Biotherapeutics approves appointment of Moin to board of directors

SAB Biotherapeutics announced that the SAB Board of Directors has approved the appointment of Andrew Moin to the Company’s Board of Directors. SAB also announced the closing of the issuance of Series A-1 Preferred Stock, the first tranche of the $130 million in private financing the company announced on Oct. 2. The gross proceeds of the issuance of Series A-1 Preferred Stock are approximately $7.5 million. Moin’s appointment, SAB Biotherapeutics’ Board is composed of nine directors, seven of whom are independent. Moin serves as Partner and Analyst at Sessa Capital, a New York based investment advisor registered with the SEC.